NewsBenzingaAnaptysBio、第3四半期EPSは0.11ドルで予想の0.51ドルを下回る、売上高は3,027万4,000ドルで予想の3,318万6,000ドルを下回る AnaptysBio、第3四半期EPSは0.11ドルで予想の0.51ドルを下回る、売上高は3,027万4,000ドルで予想の3,318万6,000ドルを下回る Benzinga 2026.11.12 21:55 (GMT+0) Open on Benzinga Other news Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says How to Play NKE Stock as Nike Risks Becoming a Forever Turnaround Story